OSI signs development agreements

Published: 3-Feb-2001


OSI Pharmaceuticals has entered into concurrent agreements with Genentech and Roche for the global co-development and commercialisation of its lead anticancer drug, OSI-774. It is currently in Phase II trials for non-small cell lung, head and neck, and ovarian cancers. Both companies have agreed to purchase US$35m of OSI stock and will pay up-front fees. Genentech will be responsible for commercialiseing the product in the US, and Roche elsewhere.

You may also like